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Abstract 
Background: The role of artificial and bioartificial liver support systems in acute-on-chronic liver failure (ACLF) is still 
controversial. We aimed to perform the first network meta-analysis comparing and ranking different liver support 
systems and standard medical therapy (SMT) in patients with ACLF.
Methods: The study protocol was registered with PROSPERO (CRD42020155850). A systematic search was con-
ducted in five databases. We conducted a Bayesian network meta-analysis of randomized controlled trials assessing 
the effect of artificial or bioartificial liver support systems on survival in patients with ACLF. Ranking was performed 
by calculating the surface under cumulative ranking (SUCRA) curve values. The RoB2 tool and a modified GRADE 
approach were used for the assessment of the risk of bias and quality of evidence (QE).
Results: In the quantitative synthesis 16 trials were included, using MARS®, Prometheus®, ELAD®, plasma exchange 
(PE) and BioLogic-DT®. Overall (OS) and transplant-free (TFS) survival were assessed at 1 and 3 months. PE significantly 
improved 3-month OS compared to SMT (RR 0.74, CrI: 0.6–0.94) and ranked first on the cumulative ranking curves 
for both OS outcomes (SUCRA: 86% at 3 months; 77% at 1 month) and 3-month TFS (SUCRA: 87%) and second after 
ELAD for 1-month TFS (SUCRA: 76%). Other comparisons did not reach statistical significance. QE was moderate for PE 
concerning 1-month OS and both TFS outcomes. Other results were of very low certainty.
Conclusion: PE seems to be the best currently available liver support therapy in ACLF regarding 3-month OS. Based 
on the low QE, randomized trials are needed to confirm our findings for already existing options and to introduce 
new devices.
Keywords: Network meta-analysis, Liver support therapy, Overall survival, Transplant-free survival, SUCRA , Plasma 
exchange, ELAD, MARS, Prometheus, BioLogic-DT
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Introduction
Acute-on-chronic liver failure (ACLF) is a clinical syn-
drome defined by the acute deterioration of chronic liver 
disease and the rapid development of organ failures, 
associated with high short-term mortality.
ACLF is due to exogenous and endogenous precipi-
tating factors called pathogen- and damage-associated 
molecular patterns (PAMPs and DAMPs) [1, 2]. The 
release of these molecules by necrosis or infection trig-
gers an excessive inflammatory response, resulting in 
organ failures. Most patients developing ACLF have pre-
existing cirrhosis, which is in itself a hyperinflammatory 
state [3, 4]. Another aggravating factor is the immune 
paralysis described by several studies [5–9], which 
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prevents effective countermeasures against infection and 
makes patients prone to serious infective complications.
Several therapies have been tested for the replacement 
of hepatic functions. So far, liver transplantation is the 
only curative therapy available. Survival rates are good, 
but availability and eligibility for transplant in ACLF dif-
fers by country [10]. In the CANONIC study, only 4.5% 
of ACLF patients received transplant. Reportedly, low 
transplant rates are due to the high prevalence of infec-
tion and organ failure. Waiting-list mortality exceeds 50% 
in this population [10].
The development of extracorporeal liver support sys-
tems dates back to the seventies with the aim to stabi-
lize patients at the time of acute decompensation when 
transplant is not available or bridge patients to transplant 
[11]. At first, these devices were designed to replace only 
excretory functions and were based on hemoperfusion 
and adsorption [12]. The newer technologies combined 
these methods with bioreactors containing hepatocytes 
creating bioartificial liver support systems with the 
potential of synthetic activity.
The Asian Pacific Association for the Study of the 
Liver (APASL) consensus guideline from 2019 states 
that “plasma exchange appears to be a promising and 
effective bridging therapy in patients with ACLF to liver 
transplant or spontaneous regeneration [1, C]” [13]. The 
European Association for the Study of the Liver (EASL) 
Clinical Practice Guidelines do not recommend liver sup-
port therapies for the treatment of ACLF, but underline 
the importance of further studies, because in specific 
subgroups ACLF seems beneficial [14].
Numerous pairwise meta-analyses of randomized con-
trolled trials (RCTs) have been published assessing short-, 
middle-, and long-term survival benefit of liver sup-
port therapies with controversial results [15–22]. These 
meta-analyses faced serious limitations, as they pooled 
together data from studies testing different devices, in 
some cases with different follow-up lengths. A network 
meta-analysis (NMA), on the other hand, can handle 
multiple interventions and rank them, if the assumption 
of transitivity is met [23].
To facilitate international discussion and consensus, we 
decided to perform the first NMA comparing all available 
and tested liver support systems to each other and stand-
ard medical therapy (SMT) in patients with ACLF and 
ranking these treatments by survival benefit.
Methods and materials
The protocol for this review was registered in the 
PROSPERO database under registration number 
CRD42020155850. There were no protocol devia-
tions. This meta-analysis was reported according to 
The PRISMA Extension Statement for Reporting of 
Systematic Reviews Incorporating Network Meta-anal-
yses of Health Care Interventions (PRISMA-NMA) [24].
Eligibility criteria
Parallel randomized controlled trials assessing the safety 
and efficacy of artificial and bioartificial liver support 
therapies in adult patients with acute-on-chronic liver 
failure (ACLF) were eligible for inclusion, regardless of 
the current availability of the tested therapy and length 
of follow-up. Conference abstracts were included to 
reduce publication bias. Crossover studies were excluded 
from the analyses of survival due to concerns about the 
carryover effect, but were included in the systematic 
review. ACLF definitions used in the included RCTs were 
accepted, as there is a lack of international consensus 
regarding this matter. For the studies published before 
ACLF was introduced as a clinical entity, the review 
authors decided eligibility based on the eligibility crite-
ria used in the study. Due to substantial heterogeneity 
regarding the definitions or the timing of measurements, 
some outcomes were included only in the qualitative syn-
thesis. Studies with shorter or longer follow-up periods 
than the assessed outcomes were also included in the sys-
tematic review.
Search strategy and selection
The systematic search was conducted up to the 15th 
December 2019 in the following databases: MEDLINE 
(via PubMed), Embase, CENTRAL, Web of Science, and 
Scopus, with the search key designed based on the PICO 
format––(“hepatic failure” OR “liver failure” OR “end-
stage liver disease” OR “cirrhosis” OR “alcoholic hepa-
titis”) AND (“liver support system” OR “liver support 
device” OR “liver assist device” OR “artificial liver” OR 
“bioartificial liver” OR “extracorporeal liver” OR “albu-
min dialysis” OR “extracorporeal cellular therapy” OR 
“MARS” OR “Prometheus” OR “fractioned plasma sepa-
ration and adsorption” OR “hemoadsorption”) AND ran-
dom*. No filters or restrictions were applied. References 
of included studies, citing articles, and authors’ accessi-
ble publications in a search engine (Google Scholar) and 
ResearchGate were hand searched for further eligible 
publications.
Data extraction
Data extraction was performed by two independent 
investigators (KO and AK) in duplicate using Endnote 
X9, Clarivate Analytics and Windows Excel 2016, Micro-
soft. In the case of discrepancies, agreement was reached 
by two experts (ZM or ZS). As a measure of inter-rater 
reliability, Cohen’s kappa coefficients (κ) for the selec-
tion of abstracts and full texts were counted. Information 
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collected from each study and additional information 
used are detailed in Additional file 1.
Risk of bias assessment and quality of evidence
The risk of bias assessment was conducted in duplicate 
using Version 2 of the Cochrane risk-of-bias tool for ran-
domized trials (RoB 2) for overall and transplant-free 
survival separately [25].
For the four outcomes assessed in the NMA, quality 
of evidence was assessed in duplicate according to the 
Grades of Recommendation, Assessment, Development 
and Evaluation Working Group’s recommendations, 
using a modified GRADE approach [26].
Statistical analysis
A Bayesian method was used to perform pairwise meta-
analyses and NMAs with the random effect model for 
overall survival (OS) and transplant-free survival (TFS). 
For the analysis of transplant-free survival, transplant 
counted as an event similar to death. In case no patient 
received liver transplantation, OS and TFS were identi-
cal. If available, data for the intention-to-treat population 
were used.
We used risk ratios (RR) for dichotomous data with 95% 
credible intervals (95% CrI). We optimized the model 
and generated posterior samples using the Monte-Carlo 
methods running in four chains. We set at least 20,000 
adaptation iterations to get convergence and 10,000 sim-
ulation iterations. Network estimates (pooled direct and 
indirect data) of each intervention compared to standard 
medical therapy and other interventions are presented 
in forest plots, summarized in a league table (as shown 
in the results section). We were unable to use the node-
splitting analysis to examine the consistency assumption 
because of the star-shaped configuration of the networks 
[27]. We ranked the interventions by their posterior 
probability by calculating the surface under cumulative 
ranking (SUCRA) curve values ranging from 0 to 100%. 
The higher the SUCRA value, and the closer to 100%, the 
higher the likelihood that a therapy is in the top rank or 
one of the top ranks; the closer to 0 the SUCRA value, the 
more likely that a therapy is in the bottom rank, or one 
of the bottom ranks [28]. We also provided rankograms, 
showing the probability of achieving certain ranks. Fre-
quentist comparison-adjusted funnel plots were created 
for 1- and 3-month OS, and Egger’s tests were performed 
to assess small-study effect. The low number of studies in 
the TFS analyses did not enable this method. In an addi-
tional analysis, methodology-based evaluation was per-
formed. All calculations were performed with R (V. 3.5.2) 
package gemtc (V. 0.8–2) along with the Markov Chain 




The systematic search yielded 2797 records. Four addi-
tional articles were identified through manual search 
and from previous meta-analyses. κ for abstracts and 
full texts was 0.87 and 0.90, respectively, marking almost 
perfect agreement in both cases. One hundred three full 
texts were assessed for eligibility. Twenty-three articles 
proved to meet the eligibility criteria for the systematic 
review and 16 were included in the data synthesis (Fig. 1).
Characteristics of the included studies
The main characteristics of the 23 eligible studies 
included in qualitative synthesis are shown in Table  1. 
Of the 16 studies, enrolling 1670 patients included in the 
meta-analysis, 15 compared a type of artificial [29–38] 
or bioartificial [39–43] liver support system to standard 
medical therapy and one study compared MARS versus 
MARS plus plasma exchange [44]. The most common 
etiologies of underlying diseases were viral infection 
and alcohol. From the 1526 participants with available 
information on gender, 1064 were males (69.8%). ACLF 
definitions, eligibility criteria, baseline characteristics, 




Survival was reported in most of the included studies, 
with greatly varying follow-up lengths. Data synthesis 
was feasible in four cases: 1-month (28–31  days) and 
3-month (84–91  days) data were pooled for overall and 
transplant-free survival. The summary of the findings for 
these four outcomes is presented in Table 2.
Plasma exchange demonstrated a statistically signifi-
cant survival benefit compared to SMT in the analysis 
for 3-month OS (RR 0.74; CrI 0.60 to 0.94), with 86% 
SUCRA, 46% probability of being the best, and 41% 
probability of being the second-best option from the six 
listed treatments (Figs. 2 and 3). PE also ranked first on 
the cumulative curves in three out of four analyses: both 
1- and 3-month OS and 1-month TFS (Fig. 2, Additional 
file 1: Figure S3, S7). In the analysis for 1-month TFS PE 
ranked second after ELAD, with 76% versus 79% SUCRA 
values, but had a slightly higher cumulative probability of 
being in the first two places than ELAD (90% versus 88%) 
(Additional file 1: Figure S11). 
MARS ranked second in both OS outcomes (Fig.  2, 
Additional file  1: Figure S3) with 73% SUCRA at 
1 month and 71% at 3 months. Concerning TFS, MARS 
ranked second last and last with SUCRA values of 27% 
at 1 month and 33% at 3 months (Additional file 1: Fig-
ures  S7, S11). Prometheus was included in both OS 
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analyses and in 3-month TFS. Only MARS, PE, and their 
combination performed better than this device in the 
OS outcomes and it ranked second after PE for 3-month 
TFS. However, the SUCRA values and the probabilities 
for the first ranks are much lower than for PE (SUCRA: 
40% for both OS and 51% for 3-month TFS, first rank 
probabilities 5% for 1-month OS, 4% for 3-month OS, 
and 13% for 3-month TFS, shown in Figs. 2, 3, Additional 
file 1: Figures S3, S4, S7, S8). Despite ELAD therapy, the 
only biological device ranked first for 1-month TFS, in 
the analysis for 3-month TFS, it had a SUCRA of 38%, 
even lower than SMT (41%). BioLogic-DT was included 
in the OS analyses and ranked second last in both cases. 
SMT had the lowest probability of being the best or sec-
ond-best option in all four analyses.
Methodology-based analyses were also performed 
grouping the albumin-based (MARS and Prometheus) 
techniques, with very similar results (only the PE-SMT 
comparison for 3-month OS reaching statistical signifi-
cance, Additional file 1: Figures S21 and S22).
Wilkinson et  al. [45] provided data only for 5-day 
survival comparing BioLogic-DT with SMT in a small 
number of patients. The device seemed to be effec-
tive in bridging to transplant. Hu et al. [46] has found 
that MARS improved the survival of patients with 
chronic severe hepatitis with multiorgan failure. You 
Fig. 1 Flowchart of study selection according to the PRISMA Statement
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et al. [47] tested the hybrid bioartificial liver support-
ing system (HBALSS) in 6 patients with similar mor-
tality rate to controls. He et  al. [48] tested the effects 
of plasma perfusion (PP), plasma exchange (PE), and 
direct hemoperfusion (DHP) compared with SMT and 
the results were reported in Chinese. A higher survival 
rate was reported in the intervention group (68.75% vs 
46.67%) for the whole study population. Extracted data 
for mortality in the ACLF subgroup by Alshamsi et al. 
did not show a significant difference (RR 0.59, 95% CI 
0.33–1.04) [19].
Long-term survival was assessed in six studies. 
Six-month survival was reported to be identical in 
both groups by Hassanein, Heemann, and Pyrsopou-
los (additionally presented at a conference, together 
with 1-year survival) [31, 38, 42]. Duan et al. reported 
higher transplant-free survival in the ELAD group, 
maintained until the end of the 5-year follow-up [40]. 
On the contrary, Thompson et  al. found comparable 
mortality in the two groups at 5  years [39]. Interest-
ingly, Qin et al. showed that in the PE group the 5-year 
cumulative survival probability was significantly 
higher (43% vs 31% survived) and have found that 
treatment added about 6 months to the life expectancy 
of patients with HBV-associated ACLF.
Hepatic encephalopathy and ammonia
Altogether ten studies reported the changes in men-
tal status, but for  hepatic encephalopathy (HE) differ-
ent scales and definitions were used (Additional file  1: 
Table S2). All studies reported improvement, which was 
statistically significant only in five cases, all using MARS 
therapy.
Ten studies reported changes in blood ammonia levels 
(Additional file  1: Table  S4). Findings are controversial 
for MARS. Prometheus and BioLogic-DT do not remove 
ammonia effectively.
Bilirubin
Changes in total bilirubin (TBIL) were reported in 
twenty studies (Additional file 1: Table S3). The results 
were not pooled on account of different treatment 
doses, measurement time points, and definitions for 
bilirubin reduction. Hassanein et  al. rightly pointed 
out that the time between the last treatment session 
and post-treatment measurements could greatly influ-
ence this outcome [38]. They showed that a single ses-
sion of MARS reduced TBIL levels significantly, but 
this difference decreased by the end of the 5-day treat-
ment period. MARS, PE, MARS combined with PE, 
Prometheus, ELAD, and HBALSS treatments signifi-
cantly reduced bilirubin levels. Krisper et al. compared 
MARS and Prometheus in a crossover design and 
reported Prometheus to be more effective in the 
removal of conjugated and unconjugated bilirubin. 
BioLogic-DT does not remove bilirubin effectively.
Bile acids
Hassanein, Heemann, and Laleman found that both 
MARS and Prometheus reduced bile acid levels sig-
nificantly (P < 0.001 and P < 0.001, respectively) [31, 38, 
49]. Krisper et al. reported that MARS and Prometheus 
remove individual bile acids with different clearance 
rates [50]. On the other hand, Meijers et  al. observed 
no significant reduction in bile acid levels after MARS 
sessions.
Creatinine and blood urea nitrogen
Changes in creatinine levels were reported in 12 cases 
(Additional file 1: Table S5). Findings for MARS and Bio-
Logic-DT are controversial regarding creatinine removal 
from the  blood, and Prometheus and plasma exchange 
therapy do not influence creatinine levels.
MARS, Prometheus, and BioLogic-DT were found to 
decrease blood urea nitrogen levels effectively.
Cytokines
TNF-α levels were reduced after 6 hours of BioLogic-
DT treatment (P = 0.04) as reported by Kramer et  al. 
[32], but only small changes were observed by Ellis 
et  al. [37]. MARS and Prometheus treatment did not 
reduce TNF-α levels [34, 51]. He et  al. reported sig-
nificant TNF-α reduction after treatment [48]. MARS 
did not change IL-6, IL-8, and IL-10 levels, similarly 
to TNF receptors 1 and 2 [34, 51]. Higher IL-8 levels 
were measured in the BioLogic-DT group [37]. Levels 
of anti-inflammatory protein IL-1 receptor antagonist 
were significantly elevated for days in ELAD-treated 
subjects [39].
Harms
In the numbers of adverse events (AEs) and reporting 
protocols, an immense heterogeneity was shown; there-
fore, quantitative data synthesis was not carried out. All 
devices were evaluated to be safe, and the number of AEs 
was comparable to the control groups. Hassanein et  al. 
described nine possibly treatment-related adverse events 
in the MARS group; however, the nature of these was not 
detailed [38]. Acute hemolysis developed in one patient in 
the ELAD group [40] and treatment was discontinued in 
several subjects due to adverse events not specified [39, 41, 
43]. Heemann et al. compared AEs in the MARS group to 
patients who received dialysis and found no significant dif-
ference. Two out of the twelve patients treated with MARS 
had fever/sepsis possibly related to the catheter [31].
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Table 2 Summary of findings




Rank Study event rates (%) Risk ratio (95% 
CrI)
















3-month overall survival (follow-up: range 84 days to 91 days)
 PE (2 RCTs) 1 334/569 (58.7%) 136/244 (55.7%) RR 0.74 (0.60 to 
0.94)
59 per 100 15 fewer per 100 
(from 23 to 4 fewer)
⨁◯◯◯
Very low
 MARS (2 RCTs) 2 12/17 (70.6%) RR 0.78 (0.38 to 
1.40)
13 fewer per 100 




 Prometheus (1 
RCT)
3 46/77 (59.7%) RR 0.97 (0.68 to 
1.40)
2 fewer per 100 (from 




 ELAD (4 RCTs) 4 78/213 (36.6%) RR 0.99 (0.76 to 
1.30)
1 fewer per 100 (from 




 BioLogic-DT (1 
RCT)
5 5/5 (100.0%) RR 1.00 (0.55 to 
2.10)
0 fewer per 100 (from 




1 month overall survival (follow-up: range 28 days to 31 days)
 PE (1 RCT) 1 122/359 (34.0%) 19/104 (18.3%) RR 0.51 (0.12 to 
2.40)
34 per 100 17 fewer per 100 




 MARS (3 RCTs) 2 109/113 (96.5%) RR 0.60 (0.15 to 
1.30)
14 fewer per 100 




 MARS + PE 
(indirect)
3 7/60 (11.7%) RR 0.60 (0.07 to 
3.20)
14 fewer per 100 




 Prometheus (1 
RCT)
4 29/77 (37.7%) RR 1.00 (0.25 to 
4.30)
0 fewer per 100 (from 




 BioLogic-DT (1 
RCT)
6 6/10 (60.0%) RR 1.10 (0.24 to 
5.40)
3 more per 100 (from 




 ELAD (3 RCTs) 7 26/117 (22.2%) RR 1.40 (0.56 to 
3.60)
14 more per 100 




3-month transplant-free survival (follow-up: range 84 days to 91 days)
 PE (1 RCT) 1 189/396 (47.7%) 42/104 (40.4%) RR 0.77 (0.51 to 
1.10)
41 per 100 11 fewer per 100 (from 
23 fewer to 5 more)
⨁⨁⨁◯
Moderate
 Prometheus (1 
RCT)
2 52/77 (67.5%) RR 0.96 (0.67 to 
1.40)
2 fewer per 100 (from 




 ELAD (4 RCTs) 4 76/217 (35.0%) RR 1.00 (0.78 to 
1.40)
0 fewer per 100 (from 




 MARS (1 RCT) 5 7/8 (87.5%) RR 1.10 (0.61 to 
2.10)
5 more per 100 (from 
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Adverse events were reported in all but four papers 
in general. The most frequent complications were 
bleeding at the site of the catheter, clotting in the 
apparatus, and thrombocytopenia. Hypotension was 
reported in patients treated with PE and Prometheus 
[33, 49].
Risk of bias assessment and quality of evidence
The quality of evidence is shown in Table  2 (see Addi-
tional file 1: Table S1 for more detail). Quality of evidence 
was moderate for PE in the analysis of OS at 1  month 
and both TFS outcomes. All other results were of very 
low certainty. The results of the risk of bias assessment 
conducted separately for OS and TFS are shown in Addi-
tional file 1: Figures S13 and S14. Overall risk of bias was 
low in 50% of the studies included in the OS analyses. 
33% carried moderate and 22% high risk of bias. For TFS, 
22% of studies carried low, 22% moderate, and 46% high 
risk of bias.
Discussion
Extracorporeal liver support therapies have been and 
will remain of fundamental interest in the management 
of ACLF [52]. However, their benefits have been debated 
for long. Therefore, we conducted the first network meta-
analysis focusing on patients with ACLF, assessing overall 
and transplant-free survival at 1 and 3 months. The analy-
ses for OS yielded similar results, with PE ranking first and 
MARS second on the cumulative ranking curves in both 
cases. From all comparisons, only plasma exchange was 
associated with a statistically significant improvement, 
when compared to SMT in the analysis of 3-month over-
all survival, but with very low certainty of evidence. Other 
comparisons did not reach statistical significance, but 
SMT had very low probabilities of being the best option in 
all analyses.
Until then, evidence on the efficacy of PE in ACLF 
mostly originated from cohort studies. The APASL con-
sensus guideline recommended the use of PE in ACLF 
Table 2 (continued)




Rank Study event rates (%) Risk ratio (95% 
CrI)
















1-month transplant-free survival (follow-up: range 28 days to 31 days)
 ELAD (2 RCTs) 1 109/264 (41.3%) 14/43 (32.6%) RR 0.47 (0.13 to 
1.20)
41 per 100 22 fewer per 100 (from 
36 fewer to 8 more)
⨁◯◯◯
Very low
 PE (1 RCT) 2 47/104 (45.2%) RR 0.52 (0.21 to 
1.20)
20 fewer per 100 (from 
33 fewer to 8 more)
⨁⨁⨁◯
Moderate
 MARS (3 RCTs) 3 60/122 (49.2%) RR 0.96 (0.50 to 
1.50)
2 fewer per 100 (from 
21 fewer to 21 more)
⨁◯◯◯
Very low
Significant results are highlighted in italic
CrI credible interval, PE plasma exchange, RCT randomized controlled trial, RR risk ratio, MARS molecular adsorbent and recirculating system, ELAD extracorporeal liver 
assist device
1 Intervention compared to SMT as reference comparator
2 Number of studies included in the direct comparison
3 Data from all studies
4 Data from studies included in the direct comparison
Fig. 2 b Studies included in the analysis for 3-month overall survival (OS). c Geometry of the network: the nodes represent the number of studies 
and the thickness of the lines corresponds to the number of direct comparisons. a League table: The league table contains the risk ratios (RR) and 
credible intervals (CrI) for every possible comparison of the interventions. Events were defined as death during the follow-up period (84–91 days). 
Significant results are highlighted in bold. d Cumulative ranking curves: On the x axis the cumulative probability of the treatment being in the first 
n rank is shown, while the y axis shows the ranks. e Surface under the cumulative ranking curves: The surface under the cumulative ranking curve 
(SUCRA) is a numeric presentation of the overall ranking and presents a single number associated with each treatment. SUCRA values range from 0 
to 100%. The higher the SUCRA value, and the closer to 100%, the higher the likelihood that a therapy is in the top rank or one of the top ranks. The 
height of each bar corresponds to the SUCRA value of the respective treatment
(See figure on next page.)
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for bridging to transplantation or recovery. The EASL 
did not find the available evidence to be sufficient for rec-
ommending the use of any liver support therapy for the 
treatment of ACLF. High-volume PE was found to reduce 
mortality and effectively remove DAMPs, TNF-α, and 
IL-6 in ALF patients in an RCT [53, 54].
The role of immune dysfunction and dysregulated 
immune response in ACLF has recently come into focus. 
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Fig. 3 Rankograms for 3-month overall survival: Rankograms show the probability (x axis) of the respective treatment achieving certain ranks 
(y axis). a Plasma exchange, b molecular adsorbent and recirculating system, c Prometheus, d extracorporeal liver assist device, e BioLogic-DT, f 
Standard medical therapy
Both hyper-inflammation and immunosuppression play 
a role in acute decompensation [1, 7]. Inflammation rep-
resented by elevated inflammatory markers was previ-
ously thought to be a consequence of ongoing infection, 
but lately endogenous inducers were identified as under-
lying causes [2]. Bioartificial devices have the potential 
of synthetic functions and contribution to the immune 
response [55]. So far, only ELAD was tested in RCTs, 
always compared to SMT. Although ELAD did not per-
form well on the cumulative ranking curves, significantly 
higher IL-1 receptor antagonist levels were measured 
during ELAD therapy than in controls [39]. Based on this 
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finding, the immunomodulatory functions of bioartificial 
devices should be further assessed.
Several new devices are being tested in animal models 
of liver failure, including both artificial and bioartificial 
ones [56, 57], and ongoing clinical trials are enrolling 
ACLF patients ([58], NCT03882346, NCT04051437). 
Other blood purification methods, such as CytoSorb ™ 
therapy, also seem promising [59, 60], but they have not 
yet been evaluated in a randomized setting. Nevertheless, 
according to a recent in vitro experimental model, Cyto-
Sorb hemoperfusion leads to an initially faster removal of 
cytokines, like TNF-α and IL-6, as well as more effective 
reduction of albumin-bound toxins, such as indirect bili-
rubin and bile acids, compared to MARS [61].
There are some strengths and several limitations to our 
study. This is the first NMA in this field using the latest 
recommendations from the Cochrane Collaboration for 
statistical analysis, risk of bias, and QE assessment. We 
evaluated OS and TFS separately, at 1 and 3  months. 
We did not pool in-hospital, short-term, and long-term 
survival data. Studies enrolling patients with hepatore-
nal syndrome were not excluded with the aim of includ-
ing cases with poorer prognosis. This new methodology 
enabled the comparison and ranking of different devices 
and highlighted the need for international consensus on 
the definition of ACLF and further trials testing already 
existing and new devices.
The absence of loops in all of the created networks lim-
its statistical analysis in Bayesian networks and results 
in wider credible intervals. Transitivity could not be 
directly tested, but we think that the differences between 
the study populations do not violate the assumption of 
transitivity. The analyses included relatively few stud-
ies, some of them only enrolling less than 10 subjects 
per group, raising concerns about the beta-type error. 
Most importantly, due to the different definitions of 
ACLF used (Table  1), patient characteristics can differ 
significantly among studies, resulting in a highly het-
erogeneous population in our study. Eligibility criteria 
and the ratio of viral and alcoholic etiology differs in the 
included studies, but all patients were diagnosed with 
ACLF. Differences in the study populations may explain 
some of the controversial results of RCTs included in 
this meta-analysis. Also, in some of the included studies 
mortality was not a primary endpoint and was reported 
additionally; therefore, bias arises. The recruitment 
period for the included trials ranges from March 1997 
until February 2015, which could impose chronological 
bias. Variance in SMT and treatment dose also could 
have influenced outcomes [62]. Due to the differences in 
treatment dose, cut-offs and reporting protocols, data on 




Plasma exchange seems to have the most beneficial effect 
at present, but liver support devices in general had higher 
probabilities for the first two ranks than SMT. Choos-
ing the best option remains in the hands of the attending 
physician.
Implication for research
International consensus is needed to standardize the defi-
nition of ACLF. Further RCTs targeting carefully selected 
subgroups of the ACLF population, using already exist-
ing and new therapeutic methods are needed to produce 
high-quality evidence for guideline development.
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